Back to Search
Start Over
An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report.
- Source :
-
NeuroImage. Clinical [Neuroimage Clin] 2020; Vol. 25, pp. 102178. Date of Electronic Publication: 2020 Jan 13. - Publication Year :
- 2020
-
Abstract
- Major depressive disorder (MDD) is considered a highly heterogeneous clinical and neurobiological mental disorder. We employed a novel layered treatment design to investigate whether cortical thickness features at baseline differentiated treatment responders from non-responders after 8 and 16 weeks of a standardized sequential antidepressant treatment. Secondary analyses examined baseline differences between MDD and controls as a replication analysis and longitudinal changes in thickness after 8 weeks of escitalopram treatment. 181 MDD and 95 healthy comparison (HC) participants were studied. After 8 weeks of escitalopram treatment (10-20 mg/d, flexible dosage), responders (>50% decrease in Montgomery-Åsberg Depression Scale score) were continued on escitalopram; non-responders received adjunctive aripiprazole (2-10 mg/d, flexible dosage). MDD participants were classified into subgroups according to their response profiles at weeks 8 and 16. Baseline group differences in cortical thickness were analyzed with FreeSurfer between HC and MDD groups as well as between response groups. Two-stage longitudinal processing was used to investigate 8-week escitalopram treatment-related changes in cortical thickness. Compared to HC, the MDD group exhibited thinner cortex in the left rostral middle frontal cortex [MNI(X,Y,Z=-29,9,54.5,-7.7); CWP=0.0002]. No baseline differences in cortical thickness were observed between responders and non-responders based on week-8 or week-16 response profile. No changes in cortical thickness was observed after 8 weeks of escitalopram monotherapy. In a two-step 16-week sequential clinical trial we found that baseline cortical thickness does not appear to be associated to clinical response to pharmacotherapy at 8 or 16 weeks.<br /> (Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Antidepressive Agents administration & dosage
Aripiprazole administration & dosage
Cerebral Cortex diagnostic imaging
Citalopram administration & dosage
Depressive Disorder, Major diagnostic imaging
Drug Therapy, Combination
Female
Humans
Longitudinal Studies
Magnetic Resonance Imaging
Male
Middle Aged
Outcome Assessment, Health Care
Antidepressive Agents pharmacology
Aripiprazole pharmacology
Cerebral Cortex drug effects
Cerebral Cortex pathology
Citalopram pharmacology
Depressive Disorder, Major drug therapy
Depressive Disorder, Major pathology
Neuroimaging methods
Subjects
Details
- Language :
- English
- ISSN :
- 2213-1582
- Volume :
- 25
- Database :
- MEDLINE
- Journal :
- NeuroImage. Clinical
- Publication Type :
- Academic Journal
- Accession number :
- 32036277
- Full Text :
- https://doi.org/10.1016/j.nicl.2020.102178